Synthesis and Combinational Antibacterial Study of 5"-Modified Neomycin

Authors

Jianjun Zhang, Utah State University
Katherine Keller, Utah State University
Jon Y. Takemoto, Utah State UniversityFollow
Mekki Bensaci, Utah State University
Anthony Litke, Utah State UniversityFollow
Przemyslaw Greg Czyryca, Allosterix Pharmaceuticals
Cheng-Wei Tom Chang, Utah State UniversityFollow

Document Type

Article

Journal/Book Title

Journal of Antibiotics

Publication Date

7-24-2009

Publisher

Japan Antibiotics Research Group

Volume

62

First Page

539

Last Page

544

Abstract

A library of 5″-modified neomycin derivatives were synthesized for an antibacterial structure–activity optimization strategy. Two leads exhibited prominent activity against both methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Antibacterial activities were measured when combined with other clinically used antibiotics. Significant synergistic activities were observed, which may lead to the development of novel therapeutic practices in the battle against infectious bacteria.

Comments

PubMed PMID: 19629142; PubMed Central PMCID: PMC2783947

Recommended Citation

Zhang, J.; Keller, K.; Takemoto, J. Y.; Bensaci, M.; Litke, A.; Czyryca, P. G.; Chang, C.-W. T. “Synthesis and Combinational Antibacterial Study of 5"-Modified Neomycin” J. Antibiot. 2009, 62, 539-544. PubMed PMID: 19629142; PubMed Central PMCID: PMC2783947.